ImmPACT Bio Granted FDA Fast Track Designation for IMPT-314 in Patients with Relapsed or Refractory Aggressive B-cell Lymphoma
ImmPACT Bio Granted FDA Fast Track Designation for IMPT-314 in Patients with Relapsed or Refractory Aggressive B-cell Lymphoma Bispecific CD19/CD20 CAR T therapy demonstrated unmatched safety and durability in UCLA-led Phase 1 study Dual targeting of CD19 and CD20 may help improve durability by overcoming treatment resistance arising from antigen […]
ImmPACT Bio to Present at the 2023 RBC Capital Markets Global Healthcare Conference
ImmPACT Bio to Present at the 2023 RBC Capital Markets Global Healthcare Conference WEST HILLS, CA; May 10, 2023 – ImmPACT Bio USA, Inc. (“ImmPACT BIO”), a clinical-stage company developing transformative logic-gate-based chimeric antigen receptor (CAR) T-cell therapies for treating cancer and autoimmune diseases, today announced that it will participate at the 2023 RBC Capital […]
ImmPACT Bio Announces Opening of California-Based GMP Facility for Clinical Production of IMPT-314, a CD19/CD20 CAR T Therapy for B-Cell Malignancies and Autoimmune Diseases
ImmPACT Bio Announces Opening of California-Based GMP Facility for Clinical Production of IMPT-314, a CD19/CD20 CAR T Therapy for B-Cell Malignancies and Autoimmune Diseases State-of-the-art 21,500 square foot facility integrates research, development, manufacturing, and testing for end-to-end autologous CAR T-cell therapy production Dosing of first patient in Phase 1/2 trial evaluating IMPT-314 in aggressive B-cell […]
ImmPACT Bio Appoints Biren Amin, M.B.A. to its Board of Directors
—Seasoned executive brings decades of experience in capital markets, finance, and corporate strategy WEST HILLS, Calif., Feb. 8, 2023 /PRNewswire/ — ImmPACT Bio USA, Inc. (“ImmPACT Bio”), a clinical-stage company developing transformative logic-gate-based chimeric antigen receptor (CAR) T-cell therapies for treating cancer, today announced the appointment of Biren Amin, M.B.A., to its board of directors. Mr. Amin has been […]
ImmPACT Bio Announces FDA Clearance of IND for Novel Bispecific CAR to Treat Aggressive B-cell Lymphoma
ImmPACT Bio Announces FDA Clearance of IND for Novel Bispecific CAR to Treat Aggressive B-cell Lymphoma JANUARY 24, 2023 Phase 1/2 clinical trial expected to launch in early 2023 and will evaluate safety and preliminary impact on disease activity of IMPT-314 WEST HILLS, Calif., January 24, 2023 — ImmPACT Bio USA, Inc. (“ImmPACT Bio”), a […]
